A comparative analysis of histone deacetylase inhibitors for the treatment of mycosis fungoides and Sézary syndrome-Reference-Cited by-同舟云学术

A comparative analysis of histone deacetylase inhibitors for the treatment of mycosis fungoides and Sézary syndrome

Published:2019-10-13 Issue:2 Volume:182 Page:497-498
ISSN:0007-0963
Container-title:British Journal of Dermatology
language:en
Short-container-title:Br J Dermatol

Author:

Papps T.¹,McCormack C.¹^ORCID,Buelens O.¹,Van der Weyden C.¹^ORCID,Twigger R.¹,Campbell B.A.²,Dickinson M.¹,Prince H.M.¹³

Affiliation:

1. Division of Cancer Medicine, Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Medical Oncology University of Melbourne Australia

2. Department of Radiation Oncology Peter MacCallum Cancer Centre Melbourne Australia

3. Molecular Oncology and Cancer Immunology Epworth Healthcare East Melbourne Victoria Australia

Publisher

Wiley

Subject

Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjd.18522

Reference7 articles.

1. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

2. Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma

3. Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: Results of a phase II trial

4. Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect

5. Lack of durable disease control with chemotherapy for mycosis fungoides and Sézary syndrome: a comparative study of systemic therapy

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. International study of treatment efficacy in SS shows superiority of combination therapy and heterogeneity of treatment strategies;Blood Advances;2023-10-31

2. Characterizing the Spectrum of Epigenetic Dysregulation Across Lymphoid Malignancies;Precision Cancer Therapies, Volume 1 ‐ Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies;2023-03-15

3. Epigenetics in the Pathogenesis and Treatment of Cutaneous T-Cell Lymphoma;Frontiers in Oncology;2021-06-24

4. Time to Next Treatment as a Meaningful Endpoint for Trials of Primary Cutaneous Lymphoma;Cancers;2020-08-17

5. Current status of histone deacetylase inhibitors in cutaneous T-cell lymphoma;Giornale Italiano di Dermatologia e Venereologia;2019-12